{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:45:57Z","timestamp":1783529157249,"version":"3.55.0"},"reference-count":209,"publisher":"Elsevier","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.ircmb.2025.01.007","type":"book-chapter","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T04:59:17Z","timestamp":1738213157000},"source":"Crossref","is-referenced-by-count":1,"title":["The key role of immunomodulatory cytokines for the development of novel NK cell-based cancer therapies"],"prefix":"10.1016","author":[{"given":"Andrea Saez","family":"de C\u00e1mara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Barriales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Etxebarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Eguizabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib1","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.ajpath.2020.05.007","article-title":"The surprising story of IL-2: From experimental models to clinical application","volume":"190","author":"Abbas","year":"2020","journal-title":"The American Journal of Pathology"},{"issue":"20","key":"10.1016\/bs.ircmb.2025.01.007_bib2","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1182\/bloodadvances.2021004589","article-title":"Activation status dictates the function of unlicensed natural killer cells in mice and humans","volume":"5","author":"Aguilar","year":"2021","journal-title":"Blood Advances"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib3","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1158\/2326-6066.CIR-16-0162","article-title":"NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing maraba virus cellular vaccine","volume":"5","author":"Alkayyal","year":"2017","journal-title":"Cancer Immunology Research"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib4","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.4049\/jimmunol.1400034","article-title":"Increased antitumor effects using IL-2 with anti-TGF-\u03b2 reveals competition between mouse NK and CD8 T cells","volume":"193","author":"Alvarez","year":"2014","journal-title":"Journal of Immunology"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.007_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113189","article-title":"IL-2 and anti-TGF-\u03b2 promote NK cell reconstitution and anti-tumor effects after syngeneic hematopoietic stem cell transplantation","volume":"12","author":"Alvarez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib6","article-title":"Infusion of host-derived unlicensed NK cells improves donor engraftment in non-myeloablative allogeneic hematopoietic cell transplantation","volume":"11","author":"Alvarez","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fimmu.2020.00007","article-title":"Indirect impact of PD-1\/PD-L1 blockade on a murine model of NK cell exhaustion","volume":"11","author":"Alvarez","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"14","key":"10.1016\/bs.ircmb.2025.01.007_bib8","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127729","article-title":"Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway","volume":"5","author":"Alvarez","year":"2019","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib9","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2015-08-665570","article-title":"Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment","volume":"127","author":"Alvarez","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2006.06.013","article-title":"Human NK cell education by inhibitory receptors for MHC class I","volume":"25","author":"Anfossi","year":"2006","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/bs.ircmb.2025.01.007_bib11","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2017-02-767541","article-title":"Anti-CD20-IL-21 fusokine: The tail wags the dog","volume":"129","author":"Ansell","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib12","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1006\/cimm.1994.1192","article-title":"Cooperation of natural killer cell stimulatory factor\/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells","volume":"156","author":"Aste-Amezaga","year":"1994","journal-title":"Cellular Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib13","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.007_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/v11100914","article-title":"Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists","volume":"11","author":"Backhaus","year":"2019","journal-title":"Viruses"},{"issue":"27","key":"10.1016\/bs.ircmb.2025.01.007_bib15","doi-asserted-by":"crossref","first-page":"44366","DOI":"10.18632\/oncotarget.17875","article-title":"New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity","volume":"8","author":"Bailey","year":"2017","journal-title":"Oncotarget"},{"issue":"26","key":"10.1016\/bs.ircmb.2025.01.007_bib16","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.1182\/blood-2010-11-316653","article-title":"Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC","volume":"117","author":"Barao","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib17","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbmt.2011.08.023","article-title":"Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation","volume":"17","author":"Barao","year":"2011","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3389\/fimmu.2019.00909","article-title":"The natural cytotoxicity receptors in health and disease","volume":"10","author":"Barrow","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-20-1002","article-title":"A fusion protein complex that combines IL-12, IL-15, and IL-18 signaling to induce memory-like NK cells for cancer immunotherapy","volume":"9","author":"Becker-Hapak","year":"2021","journal-title":"Cancer Immunology Research"},{"issue":"18","key":"10.1016\/bs.ircmb.2025.01.007_bib20","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-15-0304","article-title":"A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed\/refractory multiple myeloma","volume":"21","author":"Benson","year":"2015","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.2021011532","article-title":"Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy","volume":"139","author":"Berrien-Elliott","year":"2022","journal-title":"Blood"},{"issue":"633","key":"10.1016\/bs.ircmb.2025.01.007_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib25","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1158\/1535-7163.MCT-09-0275","article-title":"High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer","volume":"8","author":"Bessard","year":"2009","journal-title":"Molecular Cancer Therapeutics"},{"issue":"16","key":"10.1016\/bs.ircmb.2025.01.007_bib26","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood-2016-09-738211","article-title":"Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity","volume":"129","author":"Bhatt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2024.06.001","article-title":"IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy","author":"Biggi","year":"2024","journal-title":"Cytotherapy"},{"issue":"19","key":"10.1016\/bs.ircmb.2025.01.007_bib28","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","article-title":"Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education","volume":"116","author":"Bj\u00f6rkstr\u00f6m","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/iji.12461","article-title":"Activating killer cell immunoglobulin-like receptors: Detection, function and therapeutic use","volume":"47","author":"Blunt","year":"2020","journal-title":"International Journal of Immunogenetics"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-008880","article-title":"Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival","volume":"12","author":"Bommareddy","year":"2024","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.007_bib31","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/1078-0432.CCR-19-2095","article-title":"The NKG2A-HLA-E axis as a novel checkpoint in the tumor microenvironment","volume":"26","author":"Borst","year":"2020","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13384","article-title":"Natural killer cells and engagers: Powerful weapons against cancer","author":"Bottino","year":"2024","journal-title":"Immunological Reviews"},{"issue":"5769","key":"10.1016\/bs.ircmb.2025.01.007_bib33","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science (New York, N. Y.)"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158297","article-title":"Pegylated interferon \u03b1-2a triggers NK-cell functionality and specific T-cell responses in patients with chronic HBV infection without HBsAg seroconversion","volume":"11","author":"Bruder Costa","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib35","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2017-06-790204","article-title":"Decitabine enhances targeting of AML cells by CD34","volume":"131","author":"Cany","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/bs.ircmb.2025.01.007_bib36","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1158\/1078-0432.CCR-13-0568","article-title":"The IL-18 antagonist IL-18-binding protein is produced in the human ovarian cancer microenvironment","volume":"19","author":"Carbotti","year":"2013","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.007_bib37","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma","volume":"22","author":"Carlsten","year":"2016","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib38","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: Priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001647","article-title":"IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy","volume":"9","author":"Chen","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/gt.2011.37","article-title":"Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12R\u03b22 or IL-18R\u03b1","volume":"18","author":"Choi","year":"2011","journal-title":"Gene Therapy"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003894","article-title":"Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities","volume":"9","author":"Christodoulou","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002267","article-title":"Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2","volume":"9","author":"Chu","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib43","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.2022016205","article-title":"Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies","volume":"141","author":"Cichocki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1326927","article-title":"SON-1210 \u2013 A novel bifunctional IL-12 \/ IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy","volume":"14","author":"Cini","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108189","article-title":"Novel strategies exploiting interleukin-12 in cancer immunotherapy","volume":"239","author":"Cirella","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib46","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1073\/pnas.0813192106","article-title":"Cytokine-induced memory-like natural killer cells","volume":"106","author":"Cooper","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib47","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.007_bib48","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1007\/s00262-023-03492-6","article-title":"Good manufacturing practice production of CD34","volume":"72","author":"de Jonge","year":"2023","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.007_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100783","article-title":"Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant","volume":"3","author":"Demaria","year":"2022","journal-title":"Cell Reports Medicine"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.132000","article-title":"Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells","volume":"5","author":"Deng","year":"2020","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101908","article-title":"Structural basis of human IL-18 sequestration by the decoy receptor IL-18 binding protein in inflammation and tumor immunity","volume":"298","author":"Detry","year":"2022","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11912-022-01221-3","article-title":"Development of delivery systems for local administration of cytokines\/cytokine gene-directed therapeutics: Modern oncologic implications","volume":"24","author":"Dholakia","year":"2022","journal-title":"Current Oncology Reports"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2147317","article-title":"Intracavitary adoptive transfer of IL-12 mRNA-engineered tumor-specific CD8","volume":"12","author":"Di Trani","year":"2023","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/17460441.2021.1978972","article-title":"Advances in mRNA-based drug discovery in cancer immunotherapy","volume":"17","author":"Di Trani","year":"2022","journal-title":"Expert Opinion on Drug Discovery"},{"issue":"15","key":"10.1016\/bs.ircmb.2025.01.007_bib55","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-16-2981","article-title":"Successful transfer of umbilical cord blood CD34","volume":"23","author":"Dolstra","year":"2017","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib56","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jcyt.2017.03.068","article-title":"Natural killer cells differentiated in vitro from cord blood CD34","volume":"19","author":"Domogala","year":"2017","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib57","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcyt.2016.02.008","article-title":"Cryopreservation has no effect on function of natural killer cells differentiated in vitro from umbilical cord blood CD34(+) cells","volume":"18","author":"Domogala","year":"2016","journal-title":"Cytotherapy"},{"issue":"25","key":"10.1016\/bs.ircmb.2025.01.007_bib58","article-title":"Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia","volume":"119","author":"Dong","year":"2022","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib59","article-title":"Hydrogel-based co-delivery of CIK cells and oncolytic adenovirus armed with IL12 and IL15 for cancer immunotherapy","volume":"151","author":"Du","year":"2022","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib60","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.omtm.2021.10.014","article-title":"piggyBac system to co-express NKG2D CAR and IL-15 to augment the","volume":"23","author":"Du","year":"2021","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib61","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/bs.ircmb.2022.04.001","article-title":"Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment","volume":"370","author":"Dunai","year":"2022","journal-title":"International Review of Cell and Molecular Biology"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib62","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni1213","article-title":"A critical function for type I interferons in cancer immunoediting","volume":"6","author":"Dunn","year":"2005","journal-title":"Nature Immunology"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1323161","article-title":"Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects","volume":"6","author":"Eckert","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib64","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00262-016-1863-0","article-title":"Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models","volume":"65","author":"Eckert","year":"2016","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib65","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.leukres.2011.02.006","article-title":"Interleukin-21 and rituximab enhance NK cell functionality in patients with B-cell chronic lymphocytic leukaemia","volume":"35","author":"Eskelund","year":"2011","journal-title":"Leukemia Research"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib66","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-0609.1995.tb00210.x","article-title":"Synergism of interleukin-12 and interleukin-3 on development of hematopoietic progenitors","volume":"54","author":"Fardoun-Joalland","year":"1995","journal-title":"European Journal of Haematology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib67","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96219","article-title":"Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect","volume":"3","author":"Felices","year":"2018","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib68","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/2326-6066.CIR-19-0837","article-title":"Potent cytolytic activity and specific IL15 delivery in a second-generation trispecific killer engager","volume":"8","author":"Felices","year":"2020","journal-title":"Cancer Immunology Research"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib69","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1158\/1078-0432.CCR-20-4575","article-title":"Phase I trial of N-803, an IL15 receptor agonist, with rituximab in patients with indolent non-hodgkin lymphoma","volume":"27","author":"Foltz","year":"2021","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"96","key":"10.1016\/bs.ircmb.2025.01.007_bib70","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adk4893","article-title":"Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation","volume":"9","author":"Foltz","year":"2024","journal-title":"Science Immunology"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib71","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00262-018-2121-4","article-title":"An IL-15 superagonist\/IL-15R\u03b1 fusion complex protects and rescues NK cell-cytotoxic function from TGF-\u03b21-mediated immunosuppression","volume":"67","author":"Fujii","year":"2018","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"20","key":"10.1016\/bs.ircmb.2025.01.007_bib72","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood.2020006619","article-title":"CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas","volume":"136","author":"Gang","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2024.110836","article-title":"Generation of immune cells from induced pluripotent stem cells (iPSCs): Their potential for adoptive cell therapy","volume":"85","author":"Gheitasi","year":"2024","journal-title":"Human Immunology"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib75","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","article-title":"Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells","volume":"184","author":"Glassman","year":"2021","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.561553","article-title":"Umbilical cord blood and iPSC-derived natural killer cells demonstrate key differences in cytotoxic activity and KIR profiles","volume":"11","author":"Goldenson","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib77","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1158\/1535-7163.MCT-21-0030","article-title":"SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL12 and IL21, induces localized and durable antitumor immunity in preclinical models of peritoneal solid tumors","volume":"20","author":"Gonzalez-Junca","year":"2021","journal-title":"Molecular Cancer Therapeutics"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib78","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2006-04-020198","article-title":"Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells","volume":"108","author":"Grzywacz","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.007_bib79","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.802906","article-title":"Feeder cells at the interface of natural killer cell activation, expansion and gene editing","volume":"13","author":"Gurney","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib81","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.medj.2023.03.007","article-title":"An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses","volume":"4","author":"Gutierrez","year":"2023","journal-title":"Med"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib82","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s40425-019-0761-3","article-title":"Monalizumab: Inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"van Hall","year":"2019","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib83","article-title":"A recombinant oncolytic pseudorabies virus expressing","volume":"11","author":"Han","year":"2023","journal-title":"Microorganisms"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib84","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4049\/jimmunol.163.2.583","article-title":"Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively","volume":"163","author":"Hashimoto","year":"1999","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib85","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood.V67.3.722.722","article-title":"Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation","volume":"67","author":"Hercend","year":"1986","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib86","article-title":"Purification, culture, and CD19-CAR lentiviral transduction of adult and umbilical cord blood NK cells","volume":"131","author":"Herrera","year":"2020"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib87","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fimmu.2017.00755","article-title":"OP9 feeder cells are superior to M2-10B4 cells for the generation of mature and functional natural killer cells from umbilical cord hematopoietic progenitors","volume":"8","author":"Herrera","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55239-y","article-title":"Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells","volume":"9","author":"Herrera","year":"2019","journal-title":"Scientific Reports"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.007_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215418","article-title":"The race of CAR therapies: CAR-NK cells for fighting B-cell hematological cancers","volume":"13","author":"Herrera","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib90","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201529","article-title":"A robust platform for expansion and genome editing of primary human natural killer cells","volume":"218","author":"Huang","year":"2021","journal-title":"The Journal of Experimental Medicine"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib91","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/1078-0432.CCR-05-1494","article-title":"Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy","volume":"12","author":"Ino","year":"2006","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1369743","article-title":"Therapeutic potential of interleukin-21 in cancer","volume":"15","author":"Isvoranu","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-cell-free and serum-free expansion of natural killer cells using cloudz microspheres, G-Rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib94","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.4049\/jimmunol.0803900","article-title":"NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: The rheostat model","volume":"182","author":"Joncker","year":"2009","journal-title":"Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1600-065X.2008.00658.x","article-title":"Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells","volume":"224","author":"Joncker","year":"2008","journal-title":"Immunological Reviews"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib96","article-title":"Role of cytokines and growth factors in the manufacturing of iPSC-derived allogeneic cell therapy products","volume":"12","author":"Kao","year":"2023","journal-title":"Biology (Basel)"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.007_bib97","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1182\/bloodadvances.2021005047","article-title":"Cytokine-induced natural killer cell training is dependent on cellular metabolism and is defective in obesity","volume":"5","author":"Kedia-Mehta","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362775","article-title":"A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers","volume":"15","author":"Kenney","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"13","key":"10.1016\/bs.ircmb.2025.01.007_bib99","doi-asserted-by":"crossref","first-page":"16130","DOI":"10.18632\/oncotarget.7470","article-title":"IL-15 superagonist\/IL-15R\u03b1Sushi-Fc fusion complex (IL-15SA\/IL-15R\u03b1Su-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"issue":"7051","key":"10.1016\/bs.ircmb.2025.01.007_bib100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nature03847","article-title":"Licensing of natural killer cells by host major histocompatibility complex class I molecules","volume":"436","author":"Kim","year":"2005","journal-title":"Nature"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib101","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1073\/pnas.0712229105","article-title":"HLA alleles determine differences in human natural killer cell responsiveness and potency","volume":"105","author":"Kim","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib102","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"The Journal of Experimental Medicine"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib103","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2019.02.001","article-title":"The role of cytokines in the regulation of NK cells in the tumor environment","volume":"117","author":"Konjevi\u0107","year":"2019","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib104","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.103085","article-title":"A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma","volume":"99","author":"Korde","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib105","article-title":"Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1\/IL-21 mutein fusion protein","volume":"15","author":"Kroenke","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jcyt.2020.12.002","article-title":"Generating natural killer cells for adoptive transfer: Expanding horizons","volume":"23","author":"Kundu","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib107","doi-asserted-by":"crossref","first-page":"879","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib108","first-page":"903","article-title":"Transforming growth factor-beta regulates the cell cycle status of interleukin-3 (IL-3) plus IL-1, stem cell factor, or IL-6 stimulated CD34+ human hematopoietic progenitor cells through different cell kinetic mechanisms depending on the applied stimulus","volume":"22","author":"Lardon","year":"1994","journal-title":"Experimental Hematology"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.007_bib109","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib110","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"14","key":"10.1016\/bs.ircmb.2025.01.007_bib111","first-page":"4023","article-title":"Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer","volume":"62","author":"Li","year":"2002","journal-title":"Cancer Research"},{"issue":"30","key":"10.1016\/bs.ircmb.2025.01.007_bib112","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add6997","article-title":"Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering","volume":"9","author":"Li","year":"2023","journal-title":"Science Advances"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2019.11.001","article-title":"The role of interleukin-18 in pancreatitis and pancreatic cancer","volume":"50","author":"Li","year":"2019","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib114","article-title":"IPSC-derived CAR-NK cells for cancer immunotherapy","volume":"165","author":"Lin","year":"2023","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"Pt A","key":"10.1016\/bs.ircmb.2025.01.007_bib116","article-title":"An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade","volume":"101","author":"Liu","year":"2021","journal-title":"International Immunopharmacology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib117","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omto.2020.04.006","article-title":"Therapeutic cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2","volume":"17","author":"Liu","year":"2020","journal-title":"Molecular Therapy \u2013 Oncolytics"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib118","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nature Communications"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib119","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.humimm.2011.12.015","article-title":"The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation","volume":"73","author":"Luevano","year":"2012","journal-title":"Human Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087086","article-title":"Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells","volume":"9","author":"Luevano","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/bs.ircmb.2025.01.007_bib121","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1158\/0008-5472.CAN-21-0035","article-title":"An oncolytic virus expressing IL15\/IL15R\u03b1 combined with off-the-shelf EGFR-CAR NK cells targets glioblastoma","volume":"81","author":"Ma","year":"2021","journal-title":"Cancer Research"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib122","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1074-7613(00)80413-6","article-title":"IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses","volume":"4","author":"Magram","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.cytogfr.2019.05.001","article-title":"TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation","volume":"47","author":"Mancusi","year":"2019","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib124","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jcyt.2020.02.001","article-title":"Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia","volume":"22","author":"Mani","year":"2020","journal-title":"Cytotherapy"},{"issue":"22","key":"10.1016\/bs.ircmb.2025.01.007_bib125","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib126","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19","volume":"30","author":"Marin","year":"2024","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib127","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1038\/s41467-020-19094-0","article-title":"Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells","volume":"11","author":"Mark","year":"2020","journal-title":"Nature Communications"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib128","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1078-0432.CCR-16-0004","article-title":"IL-21 enhances natural killer cell response to cetuximab-coated pancreatic tumor cells","volume":"23","author":"McMichael","year":"2017","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib129","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s41435-024-00267-6","article-title":"Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer","author":"Melero","year":"2024","journal-title":"Genes and Immunity"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib131","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202317804","article-title":"Intratumoral co-injection of NK cells and NKG2A-neutralizing monoclonal antibodies","author":"Melero","year":"2023","journal-title":"EMBO Molecular Medicine"},{"issue":"19","key":"10.1016\/bs.ircmb.2025.01.007_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193147","article-title":"Next generation immuno-oncology strategies: Unleashing NK cells activity","volume":"11","author":"Mendoza-Valderrey","year":"2022","journal-title":"Cells"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib133","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib134","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000325","article-title":"Cellular cytotoxicity is a form of immunogenic cell death","volume":"8","author":"Minute","year":"2020","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib135","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/CMR.0000000000000289","article-title":"Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels","volume":"26","author":"Mirja\u010di\u0107 Martinovi\u0107","year":"2016","journal-title":"Melanoma Research"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2021.101501","article-title":"Cytokines and signaling pathways involved in differentiation potential of hematopoietic stem cells towards natural killer cells","volume":"70","author":"Montazersaheb","year":"2021","journal-title":"Tissue & Cell"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101660","article-title":"Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells","volume":"61-64","author":"Munari","year":"2022","journal-title":"Seminars in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib139","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coi.2017.01.003","article-title":"Targeting NK-cell checkpoints for cancer immunotherapy","volume":"45","author":"Muntasell","year":"2017","journal-title":"Current Opinion in Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003923","article-title":"Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression","volume":"10","author":"Nelson","year":"2022","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"13","key":"10.1016\/bs.ircmb.2025.01.007_bib142","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1084\/jem.20120944","article-title":"Sustained effector function of IL-12\/15\/18-preactivated NK cells against established tumors","volume":"209","author":"Ni","year":"2012","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib143","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040811","article-title":"Directed differentiation of mobilized hematopoietic stem and progenitor cells into functional NK cells with enhanced antitumor activity","volume":"9","author":"Oberoi","year":"2020","journal-title":"Cells"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib144","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052370","article-title":"Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy","volume":"7","author":"Ochoa","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.100978","article-title":"mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy","volume":"4","author":"Olivera","year":"2023","journal-title":"Cell Reports Medicine"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib146","doi-asserted-by":"crossref","first-page":"693","DOI":"10.4049\/jimmunol.175.2.693","article-title":"In vivo hydrodynamic delivery of cDNA encoding IL-2: Rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells","volume":"175","author":"Ortaldo","year":"2005","journal-title":"Journal of Immunology"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib147","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cytogfr.2014.11.003","article-title":"NK cells and interferons","volume":"26","author":"Paolini","year":"2015","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib148","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: Implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fimmu.2017.00369","article-title":"Regulation of the functions of natural cytotoxicity receptors by interactions with diverse ligands and alterations in splice variant expression","volume":"8","author":"Pazina","year":"2017","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib151","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","article-title":"Killer Ig-like receptors (KIRs): Their role in NK cell modulation and developments leading to their clinical exploitation","volume":"10","author":"Pende","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"27","key":"10.1016\/bs.ircmb.2025.01.007_bib152","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2011.40.0655","article-title":"Interleukin-21 has activity in patients with metastatic melanoma: A phase II study","volume":"30","author":"Petrella","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib153","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1200\/JCO.1987.5.12.1933","article-title":"In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy","volume":"5","author":"Phillips","year":"1987","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib154","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40291-021-00550-6","article-title":"Bi-specific and tri-specific NK cell engagers: The new avenue of targeted NK cell immunotherapy","volume":"25","author":"Phung","year":"2021","journal-title":"Molecular Diagnosis & Therapy"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib155","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9025835","article-title":"NK cell and CD4+FoxP3+ regulatory T cell based therapies for hematopoietic stem cell engraftment","volume":"2016","author":"Pierini","year":"2016","journal-title":"Stem Cells International"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib156","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nature Communications"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.007_bib157","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41417-023-00658-3","article-title":"Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine","volume":"30","author":"Quixabeira","year":"2023","journal-title":"Cancer Gene Therapy"},{"issue":"10","key":"10.1016\/bs.ircmb.2025.01.007_bib158","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24109038","article-title":"Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer","volume":"24","author":"Raftery","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib159","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41392-022-01058-z","article-title":"Natural killer cell homing and trafficking in tissues and tumors: From biology to application","volume":"7","author":"Ran","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib160","doi-asserted-by":"crossref","first-page":"NP83","DOI":"10.1177\/1533034615601521","article-title":"Recombinant newcastle disease virus encoding IL-12 and\/or IL-2 as potential candidate for hepatoma carcinoma therapy","volume":"15","author":"Ren","year":"2016","journal-title":"Technology in Cancer Research & Treatment"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib161","first-page":"213","article-title":"Costimulation of human natural killer cell proliferation: Role of accessory cytokines and cell contact-dependent signals","volume":"15","author":"Robertson","year":"1996","journal-title":"Natural Immunity"},{"issue":"23","key":"10.1016\/bs.ircmb.2025.01.007_bib162","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"357","key":"10.1016\/bs.ircmb.2025.01.007_bib163","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"24","key":"10.1016\/bs.ircmb.2025.01.007_bib164","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","article-title":"Cytokine activation induces human memory-like NK cells","volume":"120","author":"Romee","year":"2012","journal-title":"Blood"},{"issue":"5562","key":"10.1016\/bs.ircmb.2025.01.007_bib165","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science (New York, N. Y.)"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib166","doi-asserted-by":"crossref","first-page":"6440","DOI":"10.1038\/s41467-020-20220-1","article-title":"An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer","volume":"11","author":"Sahin","year":"2020","journal-title":"Nature Communications"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib167","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008572","article-title":"Tethered IL15-IL15R\u03b1 augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model","volume":"12","author":"S\u00e1nchez-Moreno","year":"2024","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib168","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014760","article-title":"Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation","volume":"4","author":"Schilbach","year":"2015","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib169","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function","volume":"42","author":"Schlums","year":"2015","journal-title":"Immunity"},{"issue":"21","key":"10.1016\/bs.ircmb.2025.01.007_bib170","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1158\/1078-0432.CCR-10-1809","article-title":"Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: A phase I trial","volume":"16","author":"Schmidt","year":"2010","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib171","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e14","article-title":"NK cell-based immunotherapies in cancer","volume":"20","author":"Shin","year":"2020","journal-title":"Immune Network"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib172","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s12935-021-01983-z","article-title":"Overcoming the UCB HSCs-derived NK cells dysfunction through harnessing RAS\/MAPK, IGF-1R and TGF-\u03b2 signaling pathways","volume":"21","author":"Shokouhifar","year":"2021","journal-title":"Cancer Cell International"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib173","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00262-024-03765-8","article-title":"A \u201cprime and expand\u201d strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy","volume":"73","author":"Shrestha","year":"2024","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.947648","article-title":"Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib175","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226518","article-title":"Engineering NK-CAR.19 cells with the IL-15\/IL-15R\u03b1 complex improved proliferation and anti-tumor effect","volume":"14","author":"Silvestre","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib176","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/eji.200324533","article-title":"IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors","volume":"33","author":"Sivori","year":"2003","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib177","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3389\/fimmu.2020.02156","article-title":"Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of cancer","volume":"11","author":"Sivori","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/bs.ircmb.2025.01.007_bib178","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020740","article-title":"Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process","volume":"6","author":"Spanholtz","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib179","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009221","article-title":"High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy","volume":"5","author":"Spanholtz","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.007_bib180","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","article-title":"IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells","volume":"170","author":"Strengell","year":"2003","journal-title":"Journal of Immunology"},{"issue":"7229","key":"10.1016\/bs.ircmb.2025.01.007_bib181","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nature07665","article-title":"Adaptive immune features of natural killer cells","volume":"457","author":"Sun","year":"2009","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib182","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.omto.2022.05.008","article-title":"An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition","volume":"26","author":"Sun","year":"2022","journal-title":"Molecular Therapy \u2013 Oncolytics"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib183","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood-2013-02-483503","article-title":"Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses","volume":"122","author":"Sungur","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/bs.ircmb.2025.01.007_bib184","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.4049\/jimmunol.178.12.7540","article-title":"Type I IFN contributes to NK cell homeostasis, activation, and antitumor function","volume":"178","author":"Swann","year":"2007","journal-title":"Journal of Immunology"},{"issue":"11","key":"10.1016\/bs.ircmb.2025.01.007_bib185","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"28","key":"10.1016\/bs.ircmb.2025.01.007_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn0881","article-title":"CAR memory-like NK cells targeting the membrane proximal domain of mesothelin demonstrate promising activity in ovarian cancer","volume":"10","author":"Tarannum","year":"2024","journal-title":"Science Advances"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib187","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1172\/JCI62749","article-title":"Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment","volume":"122","author":"Tarek","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/bs.ircmb.2025.01.007_bib188","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cncr.24100","article-title":"A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma","volume":"115","author":"Tarhini","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib189","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.884648","article-title":"Cytokine-induced memory-like NK cells: From the basics to clinical applications","volume":"13","author":"Terr\u00e9n","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib190","doi-asserted-by":"crossref","first-page":"6472","DOI":"10.1038\/s41598-021-85960-6","article-title":"Metabolic changes of Interleukin-12\/15\/18-stimulated human NK cells","volume":"11","author":"Terr\u00e9n","year":"2021","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib191","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: Therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Molecular Cancer"},{"issue":"5","key":"10.1016\/bs.ircmb.2025.01.007_bib192","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00262-020-02749-8","article-title":"IL-15 superagonist N-803 improves IFN\u03b3 production and killing of leukemia and ovarian cancer cells by CD34","volume":"70","author":"Van der Meer","year":"2021","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib193","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib194","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00262-016-1919-1","article-title":"High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status","volume":"66","author":"Veluchamy","year":"2017","journal-title":"Cancer Immunology, Immunotherapy: CII"},{"issue":"2","key":"10.1016\/bs.ircmb.2025.01.007_bib195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","article-title":"The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells","volume":"147","author":"Verneris","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1016\/bs.ircmb.2025.01.007_bib196","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.bjc.6600915","article-title":"Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma","volume":"88","author":"Verra","year":"2003","journal-title":"British Journal of Cancer"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib197","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4049\/jimmunol.1801137","article-title":"CD137 (4-1BB) engagement fine-tunes synergistic IL-15- and IL-21-driven NK cell proliferation","volume":"203","author":"Vidard","year":"2019","journal-title":"Journal of Immunology"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib198","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: Immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nature Immunology"},{"issue":"7","key":"10.1016\/bs.ircmb.2025.01.007_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107078","article-title":"Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34","volume":"26","author":"van Vliet","year":"2023","journal-title":"iScience"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib200","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib201","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/sj.bjc.6605502","article-title":"Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma","volume":"102","author":"Watanabe","year":"2010","journal-title":"British Journal of Cancer"},{"issue":"8","key":"10.1016\/bs.ircmb.2025.01.007_bib202","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity","volume":"175","author":"Woll","year":"2005","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.ircmb.2025.01.007_bib203","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101287","article-title":"The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy","volume":"15","author":"Xie","year":"2022","journal-title":"Translational Oncology"},{"issue":"67","key":"10.1016\/bs.ircmb.2025.01.007_bib204","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6899","article-title":"A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors","volume":"7","author":"Xue","year":"2022","journal-title":"Science Immunology"},{"issue":"3","key":"10.1016\/bs.ircmb.2025.01.007_bib205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2023.109885","article-title":"Ki67-targeted oncolytic adenovirus expressing IL-15 improves intratumoral T cell infiltration and PD-L1 expression in glioblastoma","volume":"587","author":"Zhang","year":"2023","journal-title":"Virology"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib207","article-title":"Oncolytic adenovirus: Prospects for cancer immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Frontiers in Microbiology"},{"issue":"7817","key":"10.1016\/bs.ircmb.2025.01.007_bib208","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2025.01.007_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109634","article-title":"Anti-Claudin18.2-IL-21 fusion protein bifunctional molecule has more powerful anti-tumor effect and better safety","volume":"115","author":"Zhou","year":"2023","journal-title":"International Immunopharmacology"}],"container-title":["International Review of Cell and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644825000206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T07:37:02Z","timestamp":1750750622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644825000206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":209,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2025.01.007","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}